重度哮喘生物治疗的长期疗效评估及治疗调整考量
Evaluation of Long-Term Response to Biological Therapy in Severe Asthma and Considerations for Treatment Adjustment.
作者信息
Giordani Jordan, Pini Alessandro, Pini Laura
机构信息
Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.
Department of Emergency, Anaesthesiological and Resuscitation Sciences, University Cattolica Sacro Cuore, 00168 Rome, Italy.
出版信息
J Clin Med. 2025 Apr 11;14(8):2623. doi: 10.3390/jcm14082623.
Abstract
Assessing long-term responses to biological therapies for severe asthma is critical for optimizing patient management and improving clinical outcomes [...].
摘要
评估重度哮喘生物疗法的长期反应对于优化患者管理和改善临床结局至关重要[……]。
相似文献
1
Evaluation of Long-Term Response to Biological Therapy in Severe Asthma and Considerations for Treatment Adjustment.
J Clin Med. 2025 Apr 11;14(8):2623. doi: 10.3390/jcm14082623.
2
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
3
Efficacy Assessment of Biological Treatments in Severe Asthma.
J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.
4
Considerations in the long-term management of asthma in ambulatory patients.
Am J Health Syst Pharm. 2006 May 15;63(10 Suppl 3):S14-21. doi: 10.2146/ajhp060128.
5
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.
Chest. 2024 Feb;165(2):253-266. doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.
6
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
Arch Bronconeumol. 2024 Jan;60(1):23-32. doi: 10.1016/j.arbres.2023.11.011. Epub 2023 Nov 22.
7
Optimizing care for children with difficult-to-treat and severe asthma through specialist paediatric asthma centres: expert practical experience and advice.
BMC Pediatr. 2024 Mar 27;24(1):218. doi: 10.1186/s12887-024-04707-0.
8
Cohort multiple randomized controlled trial in pediatric asthma to assess the long- and short-term effects of eHealth interventions: protocol of the CIRCUS study.
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323192. doi: 10.1177/17534666251323192. Epub 2025 Mar 12.
9
Prediction of response to biological treatment with monoclonal antibodies in severe asthma.
Biochem Pharmacol. 2020 Sep;179:113978. doi: 10.1016/j.bcp.2020.113978. Epub 2020 Apr 17.
10
Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.
Tuberk Toraks. 2023 Mar;71(1):75-93. doi: 10.5578/tt.20239910.
本文引用的文献
1
The effect of benralizumab on inflammation in severe asthma: a real-life analysis.
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241304685. doi: 10.1177/17534666241304685.
2
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.
Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29.
3
Biologics and airway remodeling in asthma: early, late, and potential preventive effects.
Allergy. 2025 Feb;80(2):408-422. doi: 10.1111/all.16382. Epub 2024 Nov 9.
4
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
N Engl J Med. 2024 Dec 19;391(24):2337-2349. doi: 10.1056/NEJMoa2406673. Epub 2024 Sep 9.
5
SANI clinical remission definition: a useful tool in severe asthma management.
J Asthma. 2024 Dec;61(12):1593-1600. doi: 10.1080/02770903.2024.2376919. Epub 2024 Jul 23.
6
Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study.
Allergol Int. 2024 Jul;73(3):406-415. doi: 10.1016/j.alit.2024.02.002. Epub 2024 Mar 12.
7
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study.
Drugs. 2023 Aug;83(12):1111-1123. doi: 10.1007/s40265-023-01905-5. Epub 2023 Jul 12.
8
Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.
Allergol Int. 2023 Jan;72(1):11-23. doi: 10.1016/j.alit.2022.11.008. Epub 2022 Dec 19.
9
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.
J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022.
10
Biologic Therapies for Severe Asthma.
N Engl J Med. 2022 Jan 13;386(2):157-171. doi: 10.1056/NEJMra2032506.
Zotero 插件